SEC Form 4 · accession 0001193125-26-401327
Tango Therapeutics, Inc. · TNGX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jessica Newcomb
Officer — Principal Accounting Officer
Period of report
Sep 22, 2026
Accepted (ET)
Sep 24, 2026 · 7:41 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001819133
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Sep 22, 2026 | S | 700 | $22.8029 | D | 66,621 | D | |
| Common StockF4,F3 | Sep 22, 2026 | S | 5,100 | $23.9683 | D | 61,521 | D | |
| Common StockF5,F3 | Sep 22, 2026 | S | 2,400 | $25.1718 | D | 59,121 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on June 23, 2026.
- F2Represents the weighted average sales price per share. The shares sold at prices ranging from $22.37 to $23.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F3The amount reported in Column 2 includes 43,666 unvested restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
- F4Represents the weighted average sales price per share. The shares sold at prices ranging from $23.52 to $24.41 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F5Represents the weighted average sales price per share. The shares sold at prices ranging from $24.59 to $25.56 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.